StreetInsider.com News Articles

Form 8-K Bolt Biotherapeutics, For: Oct 23

Fri, 23 Oct 2026 10:32:00 -0400

si-local-file:///var/storage/secattach/20261023/27226286.html

Bolt Biotherapeutics acquires Prana Therapies, raises $120M

Fri, 23 Oct 2026 09:08:47 -0400

Bolt Biotherapeutics (Nasdaq: BOLT) announced the acquisition of Prana Therapies, Inc. through a stock-for-stock reverse merger, along with a concurrent $120 million private placement, according to a company press release dated Oct. 23, 2026.

The acquisition gives Bolt access to Prana's INSPIRE platform and its lead asset, PRA-216, a bispecific antibody targeting IL-4Rα and TSLP. PRA-216 is currently in Phase 2 trials for asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis planned. Patient data from all four trials are expected beginning in the second quarter of 2027.

The private placement, structured as Series D

Bolt Biotherapeutics acquires Prana Therapies, raises $120M

Fri, 23 Oct 2026 09:08:47 -0400

The private placement, structured as Series D

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Fri, 23 Oct 2026 09:08:00 -0400

Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform
PRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2 study in EoE planned; patient data from all four trials expected beginning in the second quarter of 2027
Concurrent private placement of $120 million in upfront financing with the potential to receive up to an additional $60 million upon exercise of accompanying warrants secured from leading healthcare institutional investors is expected to fund operations into 2028
Following the transaction, Sheila Gujrathi,

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Fri, 23 Oct 2026 09:08:00 -0400

Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform
PRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2 study in EoE planned; patient data from all four trials expected beginning in the second quarter of 2027
Concurrent private placement of $120 million in upfront financing with the potential to receive up to an additional $60 million upon exercise of accompanying warrants secured from leading healthcare institutional investors is expected to fund operations into 2028
Following the transaction, Sheila Gujrathi,

Form 8-K Bolt Biotherapeutics, For: Oct 01

Tue, 06 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261006/27155529.html

Form 4 Bolt Biotherapeutics, For: Sep 16 Filed by: Nemec Sarah

Mon, 21 Sep 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260921/27086236.html

Form 4 Bolt Biotherapeutics, For: Sep 16 Filed by: Yonehiro Grant

Mon, 21 Sep 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260921/27086238.html

Form 4 Bolt Biotherapeutics, For: Sep 16 Filed by: Quinn William P.

Mon, 21 Sep 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260921/27086232.html

Form SCHEDULE 13G Bolt Biotherapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 13 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26921567.html

Form SCHEDULE 13G Bolt Biotherapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC

Thu, 13 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26921567.html

Bolt Biotherapeutics (BOLT) Misses Q2 EPS by 124c

Tue, 11 Aug 2026 17:04:58 -0400

Bolt Biotherapeutics (NASDAQ: BOLT) reported Q2 EPS of ($4.57), $1.24 worse than the analyst estimate of ($3.33). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) click here.

Form 10-Q Bolt Biotherapeutics, For: Jun 30

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905681.html

Form 10-Q Bolt Biotherapeutics, For: Jun 30

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905681.html

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update